DermBiont
Founded in 2017, DermBiont is a biotechnology company based in Boston, Massachusetts. It specializes in developing skin microbiome therapeutics to treat and prevent various skin diseases, with a focus on fungal infections.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Chromaderm
Acquisition in 2021
Chromaderm develops a topical inhibitor of melanin production as a first-in-class therapy for skin brightening, melasma, and other skin diseases associated with increased melanin production.
SeylanMED
Acquisition in 2020
SeylanMED is a biotechnology company focused on developing targeted therapies for Seborrheic Keratosis (SK). Their primary goal is to create a topical Akt inhibitor, which would be the first of its kind treatment for SK. The company's lead drug candidate, SM-020, represents a novel molecularly-targeted approach to treating this condition. SeylanMED has secured funding from angel investors, including board-certified dermatologists, and is currently operating in stealth mode.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.